ATS 2019 Virtual Final Program

520 Efficacy of Tiotropium/Olodaterol Compared with Tiotropium in Patients Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials/ R. Buhl, A. de la Hoz, F. Voss, D. Singh, G.T. Ferguson, Mainz, Germany, p.A7098 521 Reduction in COPD Symptom-Related Attacks with Budesonide/Formoterol Versus Formoterol: A Post-Hoc Analysis of the RISE Study/ G.T. Ferguson, T. Skarby, L.H. Nordenmark, A. Aksomaityte, D. Lythgoe, R. Lamarca, I.A. Gilbert, F. Trudo, Farmington Hills, MI, p.A7099 522 Overuse of Short-Acting Bronchodilators and the Risk of Exacerbation Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Short-Acting Bronchodilators/ Y. Wang, Q. Zhang, L. Xie, C. Dembek, P.S. Kamble, V. Ganapathy, Ann Arbor, MI, p.A7100 523 Treatment of First Exacerbation Predicts Future Risk of Exacerbations in Patients with COPD in the DYNAGITO Trial/ P.M. Calverley, C. Jenkins, J.A. Wedzicha, A. de la Hoz, F. Voss, K.F. Rabe, A. Anzueto, Liverpool, United Kingdom, p.A7101 524 First-in-Human Data for the Inhaled IL-4Ra Antagonist, AZD1402/PRS-060, Reveals a Promising Clinical Profile for the Treatment of Asthma/ I. Bruns, M. Fitzgerald, K. Pardali, P. Gardiner, D. Keeling, L. Axelsson, F. Jiang, J. Lickliter, D. Close, BOSTON, MA, p.A7476 525 Pragmatic Randomized Controlled Trial of Budesonide/Formoterol Reliever Therapy in Adults with Mild Asthma/ R.W. Beasley, M. Holliday, H.K. Reddel, I. Braithwaite, S. Ebmeier, R. Hancox, T. Harrison, C. Houghton, K. Oldfield, A. Papi, I.D. Pavord, M. Williams, M. Weatherall, Wellington, New Zealand, p.A7477 BEHAVIORAL • CLINICAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION D102 OPTIMIZING OUTCOMES IN COPD 1:30 p.m. - 3:30 p.m. KBHCCD Room C141/C143/C149 (Level 1) Abstract Summaries 1:30-2:00 Viewing/Discussion 2:00-3:30 Chairing: V. Prieto-Centurion, MD, ATSF, Chicago, IL A.A. Lambert, MD, MHS, Spokane, WA A.L. Koch, MD, Baltimore, MD 201 Development and Evaluation of a Targeted Care Management Intervention Across a Large Integrated Healthcare Organization for Chronic Obstructive Pulmonary Disease Patients at Risk of Acute Exacerbation/ R.A. Mularski, D.M. Mosen, S.X. Uskokovic, B.L. Skalberg, A. Haim, M.C. Turley, N.L. Lee, W.-L. Koh, Portland, OR, p.A7102 202 Standardized Inpatient Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Experience from the Cleveland Clinic/ U. Majumdar, M. Smith, A. Sood, K. Alshabani, A.H. Attaway, M. Li, J. Ketz, U.S. Hatipoglu, Cleveland, OH, p.A7103 203 Time to NIV and Mortality in AECOPD Hospital Admissions: Real World Insights from the 2008 and 2014 National COPD Audits/ A. Jayadev, R. Stone, M. Steiner, M. Roberts, Slough, United Kingdom, p.A7104 204 Title: Global Excellence in COPD (GECo) - Development of a COPD Self-Management ‘Action Plan’ for Low and Middle Income Countries/ K. Vallabhaneni, S.A. Quaderi, O. Flores, S. Pollard, T. Siddharthan, W. Checkley, J. Hurst, London, United Kingdom, p.A7105 205 Trends in COPD Prevalence, Incidence and Health Services Use in Younger Adults/ A.S. Gershon, R. McGihon, J. Luo, T. Kendzerska, T.M. To, S.D. Aaron, Toronto, Canada, p.A7106 206 Characteristics of Relatively Young Smokers at Risk of Progressive Lung Disease/ R. Webster, J.D. Crapo, E.K. Silverman, B.J. Make, J.H. Finigan, E.A. Regan, Denver, CO, p.A7107 207 Early COPD Vs. “Healthy Smokers”: Impact on Respiratory Symptoms and Mental Health. Findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)/ C. Martinez, C.O. Ejike, X. Soler, M.K. Han, A. Diaz, Marshall, MI, p.A7108 208 Clinical Markers Associated with Risk of Suicide or Drug Overdose Among Heavy Smokers - A Longitudinal Follow-Up Study of the COPDGene Cohort/ K. Hoth, E.A. Regan, B.J. Make, M.K. Han, M.G. Foreman, A.S. Iyer, S.P. Bhatt, V. Kim, J.M. Bon, X. Soler, G.L. Kinney, N.A. Hanania, K.E. Lowe, K.E. Holm, A.M. Yohannes, G. Shinozaki, J.G. Fiedorowicz, Iowa City, IA, p.A7109 209 COPD Is Associated with E-cig Use Among Non-Smokers in BRFSS 2016/ M.F. Perez, A.C. Nkiruka, O. Cheryl, E.M. Mortensen, Farmington, CT, p.A7110 210 Evaluation of Sleep in Hospitalized Patients with Chronic Obstructive Pulmonary Disease: An Observational Study/ N.H. Stewart, R. Walters, V.G. Press, B. Mokhlesi, D. Lauderdale, V.M. Arora, Omaha, NE, p.A7111 211 Predictors and Barriers to Uptake of Influenza Vaccination Among African American Patients with Chronic Obstructive Pulmonary Disease in a Large Academic Hospital/ T. Olanipekun, V.S. Effoe, C. Fotzeu, N. Bakinde, G.E. Westney, Atlanta, GA, p.A7112 212 IMPACT Study: Cost-Effectiveness of Single-Inhaler Triple Therapy for the Treatment of COPD by Patients’ Exacerbation History in Quebec/ M. Schroeder, D. Shah, A. Martin, K. Ndirangu, N. Risebrough, A.S. Ismaila, Brentford, United Kingdom, p.A7113 213 Assessment of the Impact of U.S. Medicare Competitive Bidding Program (CBP) for Home Oxygen Therapy on Medicare Program Utilization and Patient Outcomes/ G.B. Diette, C. Craver, L. Cooper, C. Marquez, T. Goss, Baltimore, MD, p.A7114 214 Receipt of Home Oxygen Prior to Admission Is an Independent Risk Factor for Readmission and Death Among Medicare Beneficiaries Hospitalized for COPD, Whose Prevalence Varies Across US Hospitals/ P.K. Lindenauer, M.S. Stefan, A. Priya, D.H. Au, L.C. Feemster, A.-Y.M. Tan, J.A. Krishnan, Springfield, MA, p.A7115 ATS 2019 • Dallas, TX 382 WEDNESDAY • MAY 22